Acute On Chronic Liver Failure (ACLF) Epidemiology Forecast Research Report 2021-2030 - ResearchAndMarkets.com

The "Acute On Chronic Liver Failure (ACLF) - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This 'Acute-On-Chronic Liver Failure ACLF)-Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Acute-On-Chronic Liver Failure (ACLF), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acute-On-Chronic Liver Failure (ACLF) Epidemiology

The Acute-On-Chronic Liver Failure (ACLF) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Acute-On-Chronic Liver Failure (ACLF) epidemiology segmented as the Total Cases of Acute-On-Chronic Liver Failure (ACLF), Cases of Acute-On-Chronic Liver Failure (ACLF) by Grades, Organ Failure Associated with Acute-On-Chronic Liver Failure, Potential participating events of Acute-On-Chronic Liver Failure. The report includes the Incident scenario of Acute-On-Chronic Liver Failure (ACLF) in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Acute-On-Chronic Liver Failure (ACLF) Epidemiology

The epidemiology segment also provides the Acute-On-Chronic Liver Failure (ACLF) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total population of Acute-On-Chronic Liver Failure (ACLF) Associated in 7MM countries was estimated to be 61,026 cases in 2020 and expected to increase at a CAGR of 0.29% for the study period, i.e., 2018-2030.

• As per the estimates, United States has the Second highest incident population of Acute-On-Chronic Liver Failure (ACLF) in 7MM.
• Among the EU5 and 7MM countries, Germany had the highest incident population of Acute-On-Chronic Liver Failure (ACLF). On the other hand, Italy had the lowest number of cases, 1,725 cases in 2020.

Report Highlights

• 10-year Forecast of Acute-On-Chronic Liver Failure (ACLF) epidemiology
• 7MM Coverage
• Total Cases of Acute-On-Chronic Liver Failure (ACLF)
• Cases of Acute-On-Chronic Liver Failure (ACLF) by Grades
• Organ Failure Associated with Acute-On-Chronic Liver Failure
• Potential participating events of Acute-On-Chronic Liver Failure

Key Questions Answered

• What will be the growth opportunities in the 7MM concerning the patient population about Acute-On-Chronic Liver Failure (ACLF)?
• What are the key findings of Acute-On-Chronic Liver Failure (ACLF) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021-2030)?
• What would be the total number of patients with Acute-On-Chronic Liver Failure (ACLF) across the 7MM during the forecast period (2021-2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021-2030)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2021-2030)?
• What are the disease risk, burden, and unmet needs of Acute-On-Chronic Liver Failure (ACLF)?
• What are the currently available treatments for Acute-On-Chronic Liver Failure (ACLF)?

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. ACLF Epidemiology Overview at a Glance

3.1. Patient Share Distribution of ACLF in 2018

3.2. Patient Share Distribution of ACLF in 2030

4. ACLF Market Overview at a Glance

4.1. Market Share (%) Distribution of ACLF in 2018

4.2. Market Share (%) Distribution of ACLF in 2030

5. Executive Summary of Acute on Chronic Liver Failure

6. Organizations

7. SWOT Analysis of Acute-on-Chronic Liver Failure

8. Disease Background and Overview

8.1. Introduction

8.2. Heterogeneity of definitions

8.3. Types of ACLF

8.4. Clinical characteristics and pathophysiology

8.5. Diagnosis of ACLF

8.6. ACLF Biomarkers

9. Country-wise Epidemiology of Acute-on-Chronic Liver Failure (ACLF)

9.1. Assumptions and Rationale: 7MM

10. Epidemiology and Patient Population

10.1. Key Findings

10.2. 7MM Total Prevalent Patient Population of Acute-on-chronic liver failure

10.3. United States

10.4. Germany

10.5. France

10.6. Italy

10.7. Spain

10.8. United Kingdom

10.9. Japan

11. Treatment

11.1. Guidelines

11.2. APASL

11.3. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

12. Case Study

13. Acute-on-chronic liver failure vs. traditional acute decompensation of cirrhosis

14. Patient Journey

15. Bibliography

16. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5lobd9

View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005332/en/